Myasthenia

Latest Articles

Article
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis
James F. Howard, Vera Bril, Ted M. Burns, et al.

Neurology May 22, 2019
Editorial
EfgartigimodA novel antibody depletion therapy in myasthenia gravis
Amanda C. Guidon, Vern C. Juel

Neurology May 22, 2019
Views & Reviews
Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodiesSystematic review
Annette Johansen, Søren Just Christensen, David Scheie, et al.

Neurology March 08, 2019
Article
MuSK myasthenia gravis monoclonal antibodiesValency dictates pathogenicity
Maartje G. Huijbers, Dana L. Vergoossen, Yvonne E. Fillié-Grijpma, et al.

Neurology - Neuroimmunology Neuroinflammation February 21, 2019